Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Atara Biotherapeutics (ATRA) Cash from Investing Activities (2022 - 2025)

Historic Cash from Investing Activities for Atara Biotherapeutics (ATRA) over the last 4 years, with Q3 2025 value amounting to -$2.4 million.

  • Atara Biotherapeutics' Cash from Investing Activities rose 8547.25% to -$2.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $13.1 million, marking a year-over-year decrease of 1387.57%. This contributed to the annual value of $8.6 million for FY2024, which is 9303.76% down from last year.
  • Latest data reveals that Atara Biotherapeutics reported Cash from Investing Activities of -$2.4 million as of Q3 2025, which was up 8547.25% from -$5.1 million recorded in Q2 2025.
  • In the past 5 years, Atara Biotherapeutics' Cash from Investing Activities ranged from a high of $70.4 million in Q3 2023 and a low of -$16.7 million during Q3 2024
  • Moreover, its 4-year median value for Cash from Investing Activities was $14.7 million (2024), whereas its average is $23.0 million.
  • In the last 5 years, Atara Biotherapeutics' Cash from Investing Activities surged by 34499.75% in 2024 and then tumbled by 17045.58% in 2025.
  • Quarter analysis of 4 years shows Atara Biotherapeutics' Cash from Investing Activities stood at $51.2 million in 2022, then plummeted by 80.58% to $9.9 million in 2023, then plummeted by 66.05% to $3.4 million in 2024, then tumbled by 171.71% to -$2.4 million in 2025.
  • Its Cash from Investing Activities was -$2.4 million in Q3 2025, compared to -$5.1 million in Q2 2025 and $17.2 million in Q1 2025.